Orphan Pacific

Orphan Pacific is a specialized Japanese pharmaceutical company dedicated to the development and commercialization of orphan drugs for rare diseases. Established in 2012 as a joint venture between CMIC Holdings and Medipal Holdings, the company leverages the clinical development expertise of CMIC and the extensive distribution network of Medipal. It serves as a strategic bridge for international biotechnology firms seeking to navigate Japan's complex regulatory landscape and introduce essential therapies to the local market. The company's portfolio primarily focuses on high-unmet-need areas, including metabolic disorders, neurology, and hepatology. Orphan Pacific manages the entire product lifecycle, from regulatory submission and clinical trials to marketing and sales within Japan.